Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in NASH
NCT04166773Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2019
- Primary completion
- Dec 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of tirzepatide in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology at 52 weeks. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04166773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04166773.